Takeda: Colorectal Neoplasms trials

The registry lists 14 Colorectal Neoplasms studies with Takeda as lead sponsor. 3 are open to participants now and 7 have results posted.

Phase 1 2Phase 2 6Phase 3 1Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in PolandRecruitingNCT07623174
• A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South KoreaRecruitingNCT07035886
• A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal CancerRecruitingNCT06562543Phase 4
• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerTerminatedNCT04844073Phase 1/2Results posted
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid TumorsCompletedNCT03261947Phase 2Results posted
• A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal CancerCompletedNCT02613221Phase 1/2Results posted
• Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal CancerTerminatedNCT02448810Phase 2Results posted
• Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCCompletedNCT02394795Phase 3Results posted
• Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal CarcinomaCompletedNCT02337946Phase 2Results posted
• Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)CompletedNCT02089737Results posted
• Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)No longer availableNCT06195514
• An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal CancerActive, not recruitingNCT05030493
• An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal CancerActive, not recruitingNCT02394834
• Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaCompletedNCT00051987Phase 2